CTMX vs. SKYE, CRVO, IMAB, RENB, INCR, RPTX, SYRS, PRQR, SCPH, and PRLD
Should you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Skye Bioscience (SKYE), CervoMed (CRVO), I-Mab (IMAB), Renovaro (RENB), InterCure (INCR), Repare Therapeutics (RPTX), Syros Pharmaceuticals (SYRS), ProQR Therapeutics (PRQR), scPharmaceuticals (SCPH), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical preparations" industry.
CytomX Therapeutics (NASDAQ:CTMX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
In the previous week, CytomX Therapeutics had 6 more articles in the media than Skye Bioscience. MarketBeat recorded 11 mentions for CytomX Therapeutics and 5 mentions for Skye Bioscience. CytomX Therapeutics' average media sentiment score of 0.56 beat Skye Bioscience's score of -0.43 indicating that CytomX Therapeutics is being referred to more favorably in the media.
67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 7.0% of CytomX Therapeutics shares are owned by insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
CytomX Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
CytomX Therapeutics currently has a consensus target price of $6.53, indicating a potential upside of 245.50%. Skye Bioscience has a consensus target price of $22.50, indicating a potential upside of 86.72%. Given CytomX Therapeutics' higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Skye Bioscience.
CytomX Therapeutics received 370 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 66.01% of users gave CytomX Therapeutics an outperform vote.
CytomX Therapeutics has a net margin of 13.87% compared to Skye Bioscience's net margin of 0.00%. CytomX Therapeutics' return on equity of -30.70% beat Skye Bioscience's return on equity.
CytomX Therapeutics has higher revenue and earnings than Skye Bioscience.
Summary
CytomX Therapeutics beats Skye Bioscience on 11 of the 14 factors compared between the two stocks.
Get CytomX Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytomX Therapeutics Competitors List
Related Companies and Tools
